متابعة
Anson Abraham
Anson Abraham
Principal Scientist - Merck & Co., Inc.
بريد إلكتروني تم التحقق منه على merck.com
عنوان
عدد مرات الاقتباسات
عدد مرات الاقتباسات
السنة
Mechanisms of interferon-β effects on bone homeostasis
AK Abraham, M Ramanathan, B Weinstock-Guttman, DE Mager
Biochemical pharmacology 77 (12), 1757-1762, 2009
642009
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons
L Kagan, AK Abraham, JM Harrold, DE Mager
Pharmaceutical research 27, 920-932, 2010
492010
Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition
AP Singh, W Krzyzanski, SW Martin, G Weber, A Betts, A Ahmad, ...
The AAPS journal 17, 389-399, 2015
482015
Novel anti-TM4SF1 antibody–drug conjugates with activity against tumor cells and tumor vasculature
A Visintin, K Knowlton, E Tyminski, CI Lin, X Zheng, K Marquette, S Jain, ...
Molecular Cancer Therapeutics 14 (8), 1868-1876, 2015
382015
First-in-class anti-immunoglobulin–like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors
LL Siu, D Wang, J Hilton, R Geva, D Rasco, R Perets, AK Abraham, ...
Clinical Cancer Research 28 (1), 57-70, 2022
372022
Partial derivative—based sensitivity analysis of models describing target-mediated drug disposition
AK Abraham, W Krzyzanski, DE Mager
The AAPS journal 9, E181-E189, 2007
372007
Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans
AK Abraham, DE Mager, X Gao, M Li, DR Healy, TS Maurer
Journal of Pharmacology and Experimental Therapeutics 330 (1), 169-178, 2009
312009
Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies
VL Chudasama, A Zutshi, P Singh, AK Abraham, DE Mager, JM Harrold
Journal of pharmacokinetics and pharmacodynamics 42, 1-18, 2015
252015
Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-β in mice
AK Abraham, L Kagan, S Kumar, DE Mager
Journal of Pharmacology and Experimental Therapeutics 334 (1), 327-332, 2010
222010
Pivotal dose of pembrolizumab: a dose‐finding strategy for Immuno‐oncology
TR Li, M Chatterjee, M Lala, AK Abraham, T Freshwater, L Jain, V Sinha, ...
Clinical Pharmacology & Therapeutics 110 (1), 200-209, 2021
192021
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
E Garralda, A Sukari, NJ Lakhani, A Patnaik, Y Lou, SA Im, T Golan, ...
ESMO open 7 (6), 100639, 2022
182022
Optimal affinity of a monoclonal antibody: guiding principles using mechanistic modeling
A Tiwari, AK Abraham, JM Harrold, A Zutshi, P Singh
The AAPS journal 19, 510-519, 2017
172017
Pharmacodynamic model of parathyroid hormone modulation by a negative allosteric modulator of the calcium-sensing receptor
AK Abraham, TS Maurer, AS Kalgutkar, X Gao, M Li, DR Healy, ...
The AAPS journal 13, 265-273, 2011
142011
Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment
JM Harrold, AK Abraham
Journal of pharmacokinetics and pharmacodynamics 41, 141-151, 2014
132014
The anti–LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study
PA Lakhani B, N., TM., Abraham AK, Luddy J, Palcza J, Chartash E, Healy J
Society for Immunotherapy of Cancer Annual Meeting, 2018
10*2018
Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage Predictions
A Tiwari, H Luo, X Chen, P Singh, I Bhattacharya, P Jasper, JE Tolsma, ...
CPT: pharmacometrics & systems pharmacology 5 (10), 565-574, 2016
102016
524O Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced …
LL Siu, D Wang, J Hilton, R Geva, D Rasco, AK Abraham, JF Markensohn, ...
Annals of Oncology 31, S462, 2020
62020
Development and validation of a multiplexed drug level assay in support of combination biologics therapy clinical studies
H Tang, K Shah, T Steinmetz, A Abraham, H Jensen, A Bouton, K Marullo, ...
Journal of Pharmaceutical and Biomedical Analysis 171, 204-211, 2019
52019
Application of mechanistic pharmacokinetic–pharmacodynamic modeling toward the development of biologics
P Singh, A Tiwari, AK Abraham, A Zutshi
Developability of Biotherapeutics: Computational Approaches (eds. Kumar, S …, 2015
32015
Methods for treating hematologic malignancies with amino-pyrrolopyrimidinone compounds
AK Abraham, MZH Farooqui, P Marinello, K Mayawala
US Patent App. 18/250,404, 2023
2023
يتعذر على النظام إجراء العملية في الوقت الحالي. عاود المحاولة لاحقًا.
مقالات 1–20